fig3

Figure 3. Antitumor effects of therapy based on DCs and oncolytic VV in a murine melanoma B16 model. (A) Experimental setup. B16-bearing C57BL/6 mice (n = 10) on Day 8 after tumor transplantation were subcutaneously (s/c) injected with antigen-loaded DCs (a); on Day 10 with VV intratumorally (i/t) administered (b); or on Day 8 DCs (s/c) followed by intratumoral injection with VV on Day 10 (c). (B) Progress curves of melanoma B16 growth. (C) The levels of cytokines in the blood serum of B16-bearing C57BL/6 mice receiving either of the monotherapies with DCs or oncolytic VV or combination therapy. (L + LPS)-loaded DCs in violet; iL-loaded DCs in dark blue; iL-loaded DCs + VV in blue; VV in green; and control in red. Data from two independent experiments are presented as mean ± S.E.M. *P < 0.05. DCs: Dendritic cells; VV: vaccinia virus; LPS: lipopolysaccharide.